Opioid Use Disorder
📧 Sign up to get email alerts when something new happens for Opioid Use Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2024-03-20FDA Approved: ZUBSOLV — Supplemental Application (Orexo US, Inc.)
FDA approved a supplemental application for ZUBSOLV, a buprenorphine/naloxone product, manufactured by Orexo US, Inc.
-
FDA approval · 2024-03-20FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for Sun Pharmaceutical's buprenorphine/naloxone product, granting regulatory authorization for this …
-
FDA approval · 2024-03-20FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for BUPRENORPHINE AND NALOXONE from Mylan Pharmaceuticals Inc., confirming regulatory action on the …
-
FDA approval · 2024-03-20FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Dr.Reddys Laboratories Inc)
FDA approved a supplemental application for a generic Buprenorphine and Naloxone product from Dr. Reddy's Laboratories Inc.
-
FDA approval · 2024-03-20FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (INGENUS PHARMACEUTICALS, LLC)
The FDA approved a supplemental application for buprenorphine and naloxone from Ingenus Pharmaceuticals, LLC, confirming approval of the gen…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2024-03-20FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Rhodes Pharmaceuticals L.P.)
FDA approved a supplemental application for the generic buprenorphine and naloxone product from Rhodes Pharmaceuticals L.P.
-
FDA approval · 2024-03-20FDA Approved: BUPRENORPHINE AND NALOXONE SUBLINGUAL FILM — Supplemental Application (Alvogen Inc.)
FDA approved a supplemental application for Buprenorphine and naloxone sublingual film from Alvogen Inc.
-
FDA approval · 2024-03-20FDA Approved: BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE — Supplemental Application (Accord Healthcare, Inc)
FDA approved a supplemental application for Accord Healthcare's generic buprenorphine hydrochloride and naloxone hydrochloride dihydrate pro…
-
FDA approval · 2024-03-20FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for buprenorphine and naloxone from Mylan Pharmaceuticals Inc., confirming the changes approved …
-
FDA approval · 2024-03-19FDA Approved: METHADONE HYDROCHLORIDE — Supplemental Application (Aurolife Pharma, LLC)
FDA approved a supplemental application for Methadone Hydrochloride from Aurolife Pharma, authorizing a generic formulation of the opioid me…
-
CLINICAL_TRIALS research · 2024-03-08Clinical Trial Update: Using Combined EEG and Non-invasive Brain Stimulation to Examine and Improve Reward Functioning in Opioid Use Disorder [NA]
A completed clinical trial evaluating combined EEG and non-invasive brain stimulation to examine and improve reward functioning in opioid us…
-
CLINICAL_TRIALS withdrawal · 2024-02-29Clinical Trial Update: Assessing Optimal XR-Buprenorphine Initiation Points in Jail [Phase 4]
Clinical trial investigating initiation points for XR-Buprenorphine in jail for opioid use disorder was withdrawn.
-
CLINICAL_TRIALS trial_result · 2024-02-20Clinical Trial Update: Buprenorphine Treatment Engagement and Overdose Prevention [NA]
A completed clinical trial evaluating buprenorphine treatment engagement and overdose prevention for opioid-use disorder, with results poste…
-
CLINICAL_TRIALS trial_result · 2024-01-30Clinical Trial Update: Disclosure Intervention for People in Recovery From Opioid Use Disorder [NA]
Clinical trial completion with results posted for a disclosure intervention in people in recovery from opioid use disorder.
-
CLINICAL_TRIALS trial_result · 2024-01-16Clinical Trial Update: A Pilot Feasibility Study of Mindfulness-Oriented Recovery Enhancement With Pregnant Women With Opioid Use Disorder [NA]
Feasibility pilot study of Mindfulness-Oriented Recovery Enhancement for pregnant women with opioid use disorder; study terminated with resu…
-
FDA approval · 2024-01-03FDA Approved: METHADONE HYDROCHLORIDE — Supplemental Application (SpecGx LLC)
FDA approved a supplemental application for Methadone hydrochloride from SpecGx LLC, approving changes to an existing generic product under …
-
FDA approval · 2024-01-03FDA Approved: METHADONE HYDROCHLORIDE — Supplemental Application (SpecGx LLC)
FDA approved a supplemental application for methadone hydrochloride (SpecGx LLC), finalizing an updated regulatory authorization under an AN…
-
FDA approval · 2023-12-31FDA Approved: METHADONE HYDROCHLORIDE — Supplemental Application (SpecGx LLC)
The FDA approved a supplemental application for methadone hydrochloride submitted by SpecGx LLC.
-
CLINICAL_TRIALS trial_result · 2023-12-26Clinical Trial Update: Initiating Substance Use Disorder Treatment for Hospitalized Opioid Use Disorder Patients. [NA]
A completed clinical trial investigating initiating treatment for opioid use disorder in hospitalized patients.
-
CLINICAL_TRIALS trial_result · 2023-12-21Clinical Trial Update: Influence of Aging on Perioperative Methadone Dosing [Phase 4]
A Phase 4 trial examining how aging affects perioperative methadone dosing for postoperative pain management and opioid use.
-
FDA approval · 2023-12-15FDA Approved: DISKETS — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for DISKETS (methadone hydrochloride) from Hikma Pharmaceuticals USA Inc., indicating an approve…
-
FDA approval · 2023-12-15FDA Approved: METHADOSE — Supplemental Application (SpecGx LLC)
FDA approved a supplemental application for Methadose (methadone hydrochloride) submitted by SpecGx LLC.
-
FDA approval · 2023-12-15FDA Approved: SUBOXONE — Supplemental Application (INDIVIOR INC.)
The FDA approved a supplemental application for Suboxone (buprenorphine hydrochloride/naloxone hydrochloride) from Indivior Inc., authorizin…
-
FDA approval · 2023-12-15FDA Approved: BUPRENORPHINE HYDROCHLORIDE — Supplemental Application (PAI Holdings, LLC dba Pharmaceutical Associates, Inc. and dba PAI Pharma)
FDA approved a supplemental application for buprenorphine hydrochloride (ANDA 090622) from PAI Holdings/PAI Pharma, confirming the approval …
-
FDA approval · 2023-12-15FDA Approved: METHADONE HYDROCHLORIDE — Supplemental Application (Mylan Institutional LLC)
The FDA approved a supplemental application for methadone hydrochloride submitted by Mylan Institutional LLC, updating regulatory status for…